Artepharm Global Announces $10 Million Investment to Erradicate Malaria From East Africa Comoros Islands
July 07 2010 - 11:46AM
Marketwired
Artepharm Global Corp. (the "Company") (OTCBB: ARGC) is pleased to
announce that an agreement has been signed between The Qater
Foundation, The Chinese Federal Government, and a private
syndication with the intent of eradicating Malaria from East
Africa's Comoros Islands using the Company's Patented ArteQuick
Malaria treatment.
The Comoros Islands are a small chain of islands in East Africa
(population 800,000) in which 28% of the residents are infected
with Malaria. In 2007 Artepharm with its patented ArteQuick Malaria
treatment reduced the Malaria rate on the Comoros Island of Moheli
from over 20% of the population to less than 1%. Strict Procedural
controls will be deployed with this upcoming trial on the rest of
the Comoros Islands with the intent of attracting support from the
World Health Organisation to back ArteQuick has the leading Global
treatment for Malaria.
See Dateline News Video of Artepharm's success in Moheli on the
Company's web site www.artepharmglobal.com.
The Qater Foundation has invested $5 million in Artepharm's
clinical trials to eradicate Malaria on the Comoros Islands. The
Qater Foundation is led by Her Highness Sheikah Mozah Bint Al
Missned . Through Her Highness's passionate leadership the Qater
Foundation is dedicated to Global Learning, Community Engagement,
Science and Technology, and Scholarship programs. See Qater
Foundation website www.qf.org.qa
The Federal Chinese Government has invested $3 million in
Artepharm's clinical trials to eradicate Malaria on the Comoros
Islands. The Balance of $2 million has been invested by a
syndication of private individuals who wish to remain
anonymous.
Malaria is the largest killer on the planet, with the kind
support of progressive groups such as the Qater Foundation and the
Chinese Government and private investors Artepharm's goal is global
eradication of Malaria.
About Artepharm Global
Artepharm Global has acquired the patent and worldwide marketing
rights for Artequick®, a natural artemisinin-based anti-malaria
drug developed by Artepharm Co. Artepharm Co. is a modern
pharmaceutical company involved in R&D and the manufacturing of
artemisinin-based anti-malarias and anti-viral traditional Chinese
medicines. It was jointly established by a group of experts
specializing in the research of Qinghao, commonly known as
Artemisia annua. For more information got to
www.artepharmglobal.com.
Safe Harbour Statements
Except for the statements of historical fact contained herein,
the information presented in this news release constitutes
"forward-looking statements" as such term is used in applicable
United States and Canadian laws. These statements relate to
analyses and other information that are based on forecasts of
future results, estimates of amounts not yet determinable and
assumptions of management. Any statements that express or involve
discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, assumptions or future events or
performance (often, but not always, using words or phrases such as
"expects" or "does not expect", "is expected", "anticipates" or
"does not anticipate", "plans, "estimates" or "intends", or stating
that certain actions, events or results "may", "could", "would",
"might" or "will" be taken, occur or be achieved) are not
statements of historical fact and should be viewed as
"forward-looking statements". Such forward looking statements
involve known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements of
the Company to be materially different from any future results,
performance or achievements expressed or implied by such
forward-looking statements. Such risks and other factors include,
among others, the actual results of exploration activities, the
availability of capital to fund programs and the resulting dilution
caused by the raising of capital through the sale of shares,
accidents, labour disputes and other risks of the mining industry
including, without limitation, those associated with the
environment, delays in obtaining governmental approvals, permits or
financing or in the completion of development or construction
activities, title disputes or claims limitations on insurance
coverage. Although the Company has attempted to identify important
factors that could cause actual actions, events or results to
differ materially from those described in forward-looking
statements, there may be other factors that cause actions, events
or results not to be as anticipated, estimated or intended. There
can be no assurance that such statements will prove to be accurate
as actual results and future events could differ materially from
those anticipated in such statements. Accordingly, readers should
not place undue reliance on forward-looking statements contained in
this news release and in any document referred to in this news
release.
Forward looking statements are made based on management's
beliefs, estimates and opinions on the date the statements are made
and the Company undertakes no obligation to update forward-looking
statements if these beliefs, estimates and opinions or other
circumstances should change, except as required by applicable law.
Such forward-looking statements reflect our current views with
respect to future events and are subject to certain risks,
uncertainties and assumptions, including, the risks and
uncertainties outlined in our most recent financial statements and
reports and registration statement filed with the United States
Securities and Exchange Commission (the "SEC") (available at
www.sec.gov) and with Canadian securities administrators (available
at www.sedar.com). Such risks and uncertainties may include, but
are not limited to, the risks and uncertainties set forth in the
Company's filings with the SEC, such as the ability to obtain
additional financing, the effect of economic and business
conditions, the ability to attract and retain skilled personnel and
factors outside the control of the Company. These forward-looking
statements are made as of the date of this news release, and the
Company assumes no obligation to update the forward-looking
statements or to update the reasons why actual results could differ
from those projected in the forward-looking statements, except as
required by applicable law. Although the Company believes that the
beliefs, plans, expectations and intentions contained in this news
release are reasonable, there can be no assurance those beliefs,
plans, expectations or intentions will prove to be accurate.
Investors should consider all of the information set forth herein
and should also refer to the risk factors disclosed in the
Company's periodic reports filed from time-to-time with the SEC.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy securities of the Company nor shall
there be any sale of these securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction.
Contacts: Artepharm Global Corp. (604) 575-3552
www.artepharmglobal.com
Arion (CE) (USOTC:ARGC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Arion (CE) (USOTC:ARGC)
Historical Stock Chart
From Aug 2023 to Aug 2024